Multimodality treatment including ONCEPT for canine oral melanoma: A retrospective analysis of 131 dogs. Issue 4 (22nd April 2020)

• Record Type: Journal Article
• Authors: Turek, Michelle; LaDue, Tracy; Looper, Jayme; Nagata, Koichi; Shiomitsu, Keijiro; Keyerleber, Michele; Buchholz, Julia; Gieger, Tracy; Hetzel, Scott
• Is Part Of: Veterinary radiology & ultrasound. Volume 61:Issue 4(2020)
• Page Start: 471
• Page End: 480
• Publication Date: 2020-04-22
• Subjects: hypofractionation -- immunotherapy -- radiation -- tumor vaccine -- veterinary; Veterinary radiology -- Periodicals; Radiologie vétérinaire -- Périodiques; Échographie vétérinaire -- Périodiques; Radiography -- Periodicals; Ultrasonography -- Periodicals; Diagnosis -- Periodicals; Veterinary Medicine -- Periodicals; Societies, Medical -- Periodicals; 636.089607
• DOI: 10.1111/vru.12860
• Languages: English
• ISSNs: 1058-8183

Abstract

Abstract: Canine oral melanoma (OM) is an aggressive cancer with a high rate of metastasis. Surgery and/or radiotherapy (RT) are effective local treatments, yet many dogs succumb to distant metastasis. Immunotherapy represents an attractive strategy for this potentially immunogenic tumor. The objective of this multi‐institutional retrospective study was to examine the clinical outcome of dogs with OM treated with ONCEPT melanoma vaccine. Most dogs also underwent surgery and/or RT (8 Gy × four weekly fractions). Dogs with distant metastasis at diagnosis and those receiving concurrent chemotherapy were excluded. One hundred thirty‐one dogs treated with ONCEPT were included: 62 had adequate local tumor control defined as complete tumor excision or irradiation of residual microscopic disease; 15 were treated in the microscopic disease setting following an incomplete excision without adjuvant RT; and 54 had gross disease. Median time to progression, median progression‐free survival, and median tumor‐specific overall survival were 304, 260, and 510 days, respectively. In multivariable analysis, presence of gross disease correlated negatively with all measures of clinical outcome. Other negative prognostic indicators were primary tumor ≥2 cm, higher clinical stage (stages 2 and 3), presence of lymph node metastasis at diagnosis, and caudal location in the oral cavity. Radiotherapy had a protective effect against tumor progression. To date, this is the largest reported series of dogs with OM treated with ONCEPT. Several previously reported prognostic indicators were confirmed.